Oklahoma H7N9 Bird Flu News Monitoring Service

Scientific Federation invites all the participants from all over the world to attend Annual International Pathology Conference during May 21-22, 2018 at Valencia, Spain which includes Keynote presentations, Oral talks, Poster presentations and Exhibitions.

SMi is delighted to announce its 2nd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 21st - 22nd May 2018. The global market for Highly Potent Active Pharmaceutical Ingredients is currently on a growth fast track, largely driven by its major use in oncology for cancer treatment and more often in the form of ADCs. Over a quarter of drugs worldwide now contain HPAPIs, as they have proven to be more effective than other APIs. However, working with APIs high in potency and cytotoxicity comes with many regulations and requirements, and presents pharmaceutical companies with challenges such as handling, containment, cost and security questions. This conference will cover many important and in-demand aspects of the HPAPI industry, creating a ...

SMi is pleased to present the return of the 18th annual Pain Therapeutics Conference taking place on 21st – 22nd May 2018, London, UK. We have worked hard to bring together an elite speaker panel to educate and inspire our delegates through the exploration of innovative approaches and novel targets in analgesic medicine. Attendees will be able to network with industry experts from leading pharma companies, biotech and academics to name but a few. If you want to discover the future of pain therapeutics and be a part of the conversation, visit www.pain-therapeutics.co.uk/EVVNT 2018 Highlights • Explore the possibilities of DNA-based, disease modifying treatments for painful diabetic neuropathy with ViroMed • Overcome the challenges of patient recruitment and the placebo response ...

About HPAPI: SMi is delighted to announce its 2nd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 21st - 22nd May 2018. The global market for Highly Potent Active Pharmaceutical Ingredients is currently on a growth fast track, largely driven by its major use in oncology for cancer treatment and more often in the form of ADCs. Over a quarter of drugs worldwide now contain HPAPIs, as they have proven to be more effective than other APIs. However, working with APIs high in potency and cytotoxicity comes with many regulations and requirements, and presents pharmaceutical companies with challenges such as handling, containment, cost and security questions. This conference will cover many important and in-demand aspects of the HPAPI ...

This event is designed for pharmaceutical, biotech and medical device professionals with responsibilities in the following areas: - Product Recalls - Patient Safety - Product Safety - Product Quality - QA/QC - Postmarketing Surveillance - Quality Systems and Engineering - Quality Compliance and Audits - Complaint Handling - Medical/Consumer/Regulatory/Clinical Affairs - Product Complaints - Compliance - CMO Management - Business Support Coordination - Product Surveillance - Clinical Operations - Quality Compliance - QA and Supply Integration - Global Device Coordination This conference is also of interest to: - Drug Safety and Complaint Software Companies - Consulting Firms To this: Each year, the number of drug and medical device increase on the market and so does the number of recalls. ...

The Chronic Kidney Disease Drug Development Summit is industry’s first end-to-end drug development networking and discussion forum, dedicated to overcoming challenges drug developers face in developing chronic kidney disease therapeutics more efficacious than the current standard of care. Developed in combination with experts from Boehringer Ingelheim, Bayer, Astrazeneca, Johnson & Johnson and many more, this industry focused forum focuses on lessons learnt from CKD drug development failures, molecular understanding and reclassification towards comprehensive precisions medicine and the potential of next generation therapeutics to deliver efficacy above and beyond angiotensin converting enzyme (ACE) inhibitors and ALT1 receptor antagonists (ARBs). Be part of the cross-industry ...

As the demand for information outside of approved labeling continues to rise, the FDA has been called by the industry to provide guidance that governs off-label communications. The regulatory landscape that monitors this space is often blamed for limiting the amount of information received by patients and restricting their ability to make well-informed decisions. Given the public health issues at stake and the public interest involved, it is imperative that this event details the importance of the timely communication of truthful scientific information that currently challenges pharmaceutical, biotech, and medical device professionals. The 2018 Off-Label Regulatory Compliance Congress also explores the ever-changing regulatory landscape and explains how professionals can work with ...

During clinical trials, inspections provide a framework to ensure quality and integrity of care, data and drug performance. As sponsors of clinical trials, it is important for pharmaceutical companies to ensure GCP guidelines are upheld by implementing inspection readiness. These inspections, often conducted by the FDA, EMA, MHRA and other regulatory authorities, all have unique regulations and caveats. These nuances mean that becoming — and remaining — inspection-ready can be a difficult, time-consuming battle. Because inspections can occur without notice, sites must be prepared for visits from many different stakeholders over the course of a clinical trial. Join the 4th European Clinical Trials Inspection Readiness Summit and inspire an organisational culture that prioritises ...

MMCC gives you the knowledge and strategies you need • Gain regulatory • Adopt alternative payment • Innovate care to improve quality for your How? Talk freely with state officials, Association CEOs, CMS, and health plans to get candid answers to your • 5+Medicaid Directors from Kansas, North Carolina, Washington D.C., Maryland, and • Network with policy makers and executive leadership from ACAP, MHPA, and Hear outcomes from case studies and implications on the latest policies and programming for Medicaid Managed Care in 2018 and beyond: • Two break out tracks on Specialty Populations and Programs & Addressing the Opioid • The NHCAA will host a panel discussion moderated by Louis Saccoccio, CEO of NHCAA, as they address ...